|
WO2014083571A1
|
|
A process for the preparation of alcaftadine
|
|
WO2014125500A1
|
|
A process for preparation of olanzapine pamoate
|
|
WO2014125501A1
|
|
An improved process for preparation of sugammadex sodium
|
|
WO2011121594A1
|
|
A process for the preparation of itraconazole
|
|
WO2011121596A2
|
|
Crystal modification of moxifloxacin hydrochloride
|
|
WO2011121597A1
|
|
A PROCESS FOR THE PREPARATION OF 5-SUBSTITUTED 3-(5-NITRO-4-THIOCYANATOPYRIMIDIN-2-YL)-3H-BENZO [d]-IMIDAZOLE
|
|
WO2011121595A1
|
|
A process for the preparation of rosuvastatin calcium
|
|
WO2010106551A2
|
|
A process for the manufacture of pure anhydrous aripiprazole form b
|
|
WO2011045807A2
|
|
A novel process to manufacture (2r,3s)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol
|
|
EP1809637A1
|
|
An improved process for the preparation of levofloxacin hemihydrate
|
|
WO2005080401A1
|
|
Process for the preparation of olanzapine form 1 useful as antipsychotic drug
|
|
WO02090339A1
|
|
A process for preparing 1-methyl-3-phenyl-piperazine
|
